Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06693102

Digital Intervention Targeting Cancer-related Cognitive Impairments

Cognitive deficits are frequently reported following cancer treatment and can significantly impact daily functioning. These cognitive impairments often persist for years after cancer treatment. This study aimed to examine several aspects of a newly developed digital intervention designed to address cognitive impairments. Specifically, it focused on: (1) evaluating the preliminary effects of the intervention, (2) identifying predictors of treatment response, (3) assessing the feasibility of both the intervention and the study design, (4) gathering participant feedback on the intervention, and (5) testing the applicability of the Norwegian version of the Working Memory Questionnaire within this patient group.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Haukeland University Hospital

Bergen, 5002, Norway

Location contact

Sunniva Brurok Myklebost, PhD

CONTACT

[email protected]

0047 55556767

Sunniva Brurok Myklebost, PhD

CONTACT

About this study

Many cancer survivors report cognitive challenges, including problems with concentration, attention, memory, processing speed, and executive functions. These cognitive impairments can persist for years after cancer treatment and are associated with reduced functioning at home and work.

Several approaches for managing cognitive difficulties are described in the literature. One approach is drill-and-practice interventions involving repetitive cognitive training, often employing computer-based tasks that increase in difficulty. Other interventions focus on strategy-based exercises, teaching patients to apply coping strategies in everyday situations. Additionally, psychoeducation is an important component in treating cognitive impairments.

Access to interventions for cognitive impairments remains limited. This limited may be a consequence of limited healthcare professionals resources. One potential solution is to offer digital interventions. The research literature shows that digital interventions are as effective as face-to-face treatment for mental health conditions such as anxiety and depression. In a previous study, we also found that digital interventions for cognitive impairments in depression, to be feasible. Offering digital interventions for cancer-related cognitive impairments might therefore be a promising approach for addressing one of the most common late effects following cancer treatment.

This study aims to assess the preliminary effects and the feasibility of a digital intervention for cancer-related cognitive impairments. Specifically, it aims to reduce self-reported cancer-related cognitive impairments. Additionally, we will examine whether the intervention increase performance on objectively measured cognitive tests. Other outcomes are rumination, life satisfaction, fatigue, depressive symptoms, and anxiety symptoms. Qualitative feedback from participants on their experience with the intervention will be used to refine the program. We will also assess the feasibility of a recently translated questionnaire for measuring working memory in this patient group. The study will include 60 cancer survivors. Thirty of these will receive the digital intervention and 30 will receive paper and pencil crossword and sudoku tasks.

The research questions are:

  • What preliminary changes in self-reported cognitive impairments and other clinical outcomes are observed among cancer survivors after receiving the digital intervention?
  • To what extent do clinical and demographic factors influence the usage and response to a digital intervention for cognitive impairments following cancer treatment?
  • How feasible is the newly developed digital intervention for cognitive impairments?
  • How do cancer survivors experience a newly developed digital intervention for cognitive impairments?
  • How effective is the translated version of the Working Memory Assessment Questionnaire in measuring cognitive impairments among Norwegian cancer survivors?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

The target group consists of individuals who have previously undergone cancer treatment (N=60).

Inclusion criteria

  • Age between 18 and 65 years,
  • Self-reported cognitive difficulties that are perceived to impact daily functioning (PCI <44 FACT-Cog),
  • Have received cancer treatment,
  • Completed curative treatment at least six months prior,
  • Proficient in speaking and writing Norwegian,
  • Access to a computer, tablet, or smartphone, and the internet.

Exclusion criteria

  • Neurological disorders (e.g., ADHD, MS, autism),
  • History of severe head injury,
  • Current moderate or severe depression (PHQ-9 score >14),
  • Previously diagnosed with serious mental disorders, such as substance abuse, bipolar disorder, or psychotic disorders.

Treatment and study plan

Digital intervention targeting cancer-related cognitive impairments

Behavioral

The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.

Crossword and sudoku taks

Behavioral

Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.

Primary outcomes

  1. The Functional Assessment of Cancer Therapy- Cognitive Function

    Time frame: pre-assessment to two-year follow-up

    The Functional Assessment of Cancer Therapy- Cognitive Function (FACT-Cog) is a validated questionnaire consisting of 37 items designed to assess cognitive difficulties in cancer survivors. It includes four subscales: perceived cognitive impairment, cognitive abilities, feedback from others, and the impact of cognitive decline on quality of life. Total scores ranges from 0-148. Higher scores indicate better cognitive function.

Secondary outcomes

  1. Digit Span Wechsler Adult Intelligence Scale-IV

    Time frame: Pre- to six-month follow-up assessments

    Digit Span Wechsler Adult Intelligence Scale-IV measures auditory attention span and working memory. Numbers are read aloud to participants, who repeat the sequence. The sequence length increases, and participants also repeat sequences backward. This test

Other outcomes

  1. Rumination response scale

    Time frame: pre- to two year follow-up assessment

    Rumination response scale (RRS) consists of 22 items measuring aspects of rumination. Total scores ranges from 22-88. Higher scores indicate greater levels of rumination. The RRS can be divided into three subscales: depression-related thoughts, brooding, and reflection.

  2. Patient Health Questionnaire-9

    Time frame: Pre- to two-year follow-up assessment

    Patient Health Questionnaire-9 (PHQ-9) onsists of nine items that assess depressive symptoms. Scores ranges from 0-27. Higher scores indicate more symptoms. .

  3. The Functional Assessment of Chronic Illness Therapy-Fatigue

    Time frame: Pre- to two years follow-up assessments

    The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT) is a 13-item questionnaire that assesses fatigue and its implications for daily functioning. Total scores ranges from 0 to 52. Higher scores represents less fatigue.

  4. The Satisfaction with Life Scale

    Time frame: Pre-assessment to two-year follow-up

    The The Satisfaction with Life Scale (SWLS) measure life satisfaction. Total scores ranges from 5-35. Higher scores indicate greater level of life satisfaction. This questionnaire consists of five items.

  5. Credibility and Expectancy Questionnaire

    Time frame: First week after receiving the intervention.

    The Credibility and Expectancy Questionnaire (CEQ) measure treatment credibility and expectancy. The rating scale ranges from 0-10 where higher scores indicate better credibility and expectancy.

  6. California Verbal Learning Test II

    Time frame: Pre- to six-month follow-up assessments.

    The California Verbal Learning Test II (CVLT-II is a neuropsychological word list test measuring verbal short-term and long-term memory.

  7. Color-Word Interference Test Delis-Kaplan Executive Function System

    Time frame: Pre- to six month follow-up assessments.

    The Color-Word Interference Test, from the Delis-Kaplan Executive Function System battery (D-KEFS), consists of four subtests. Two conditions measure processing speed and mental efficiency, where participants say the ink color of squares and read color names in black ink. The following conditions measure inhibition and focus-shifting, with one condition requiring participants to say the ink color of incongruent words, and the last requiring participants to switch between naming ink color and reading color words depending on whether a frame surrounds the word.

  8. Word and Category Fluency Delis-Kaplan Executive Function System

    Time frame: Pre- six month follow-up assessments.

    The Word and Category Fluency, from the Delis-Kaplan Executive Function System (D-KEFS), is a neuropsychological test measuring verbal fluency. The test has three conditions: producing words that start with certain letters, naming items within categories, and alternating between categories.

  9. The Generalized Anxiety Disorder-7

    Time frame: Pre-assessment to two-year follow-up.

    The Generalized Anxiety Disorder-7 (GAD-7) consists of seven items that measure symptoms of anxiety. Total scores ranges from 0-21. Higher scores indicating more symptoms of anxiety.

Study contacts

Contact information is provided by the study sponsor or research team.

Sunniva Brurok Myklebost, PhD

CONTACT

[email protected]

0047 55556767

tine Nordgreen, PhD

CONTACT

[email protected]

0047 55 559862

Sponsors and collaborators

Lead sponsor

Haukeland University Hospital

Other

Collaborators

  • The Research Council of Norway

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Nov 18, 2024
Registry last updated
Nov 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.